Log in

NASDAQ:NOVN - Novan Stock Price, Forecast & News

$0.22
-0.12 (-35.30 %)
(As of 02/28/2020 04:00 PM ET)
Today's Range
$0.22
Now: $0.22
$0.28
50-Day Range
$0.22
MA: $0.56
$0.75
52-Week Range
$0.22
Now: $0.22
$3.72
Volume11.14 million shs
Average Volume434,661 shs
Market Capitalization$6.03 million
P/E RatioN/A
Dividend YieldN/A
Beta2.3
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NOVN
CUSIPN/A
Phone919-485-8080

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.90 million
Book Value($0.87) per share

Profitability

Net Income$-12,670,000.00
Net Margins-625.84%

Miscellaneous

Employees47
Market Cap$6.03 million
Next Earnings Date3/25/2020 (Estimated)
OptionableNot Optionable

Receive NOVN News and Ratings via Email

Sign-up to receive the latest news and ratings for NOVN and its competitors with MarketBeat's FREE daily newsletter.


Novan (NASDAQ:NOVN) Frequently Asked Questions

What is Novan's stock symbol?

Novan trades on the NASDAQ under the ticker symbol "NOVN."

How were Novan's earnings last quarter?

Novan Inc (NASDAQ:NOVN) issued its quarterly earnings data on Friday, May, 12th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.24. The firm earned $0.10 million during the quarter, compared to analyst estimates of $10.80 million. View Novan's Earnings History.

When is Novan's next earnings date?

Novan is scheduled to release their next quarterly earnings announcement on Wednesday, March 25th 2020. View Earnings Estimates for Novan.

What price target have analysts set for NOVN?

3 brokerages have issued twelve-month target prices for Novan's stock. Their forecasts range from $0.50 to $1.50. On average, they expect Novan's stock price to reach $1.00 in the next year. This suggests a possible upside of 354.8% from the stock's current price. View Analyst Price Targets for Novan.

What is the consensus analysts' recommendation for Novan?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novan in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novan.

Has Novan been receiving favorable news coverage?

Media stories about NOVN stock have been trending very negative recently, InfoTrie reports. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Novan earned a news impact score of -4.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the next few days. View News Stories for Novan.

Are investors shorting Novan?

Novan saw a increase in short interest in the month of February. As of February 14th, there was short interest totalling 399,500 shares, an increase of 111.7% from the January 30th total of 188,700 shares. Based on an average daily volume of 495,900 shares, the short-interest ratio is presently 0.8 days. Approximately 2.4% of the shares of the stock are sold short. View Novan's Current Options Chain.

Who are some of Novan's key competitors?

What other stocks do shareholders of Novan own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novan investors own include Melinta Therapeutics (MLNT), SCYNEXIS (SCYX), MannKind (MNKD), Trevena (TRVN), Vuzix (VUZI), Valero Energy (VLO), Washington Prime Group (WPG), Biocept (BIOC), Cirrus Logic (CRUS) and Heron Therapeutics (HRTX).

Who are Novan's key executives?

Novan's management team includes the folowing people:
  • Mr. G. Kelly Martin, CEO & Director (Age 60)
  • Ms. Paula Brown Stafford, Pres, COO & Director (Age 54)
  • Mr. John M. Gay, VP of Fin., Corp. Controller, Principal Financial Officer and Corp. Sec. (Age 42)
  • Dr. Nathan Stasko, Co-Founder & Chief Scientific Officer (Age 39)
  • Dr. Carri Geer, Sr. VP & CTO

When did Novan IPO?

(NOVN) raised $46 million in an IPO on Wednesday, September 21st 2016. The company issued 3,800,000 shares at $11.00-$13.00 per share. Piper Jaffray served as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Novan's major shareholders?

Novan's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Cardinal Capital Management (0.19%) and Vigilant Capital Management LLC (0.11%). Company insiders that own Novan stock include G Kelly Martin, John M Gay, John W Palmour, Life Sciences Holdings L Malin, Paula B Stafford and Robert Alexander Ingram. View Institutional Ownership Trends for Novan.

Which institutional investors are buying Novan stock?

NOVN stock was purchased by a variety of institutional investors in the last quarter, including Cardinal Capital Management and Vigilant Capital Management LLC. Company insiders that have bought Novan stock in the last two years include G Kelly Martin, John M Gay, John W Palmour, Paula B Stafford and Robert Alexander Ingram. View Insider Buying and Selling for Novan.

How do I buy shares of Novan?

Shares of NOVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Novan's stock price today?

One share of NOVN stock can currently be purchased for approximately $0.22.

How big of a company is Novan?

Novan has a market capitalization of $6.03 million and generates $4.90 million in revenue each year. The company earns $-12,670,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis. Novan employs 47 workers across the globe.View Additional Information About Novan.

What is Novan's official website?

The official website for Novan is http://www.novantherapeutics.com/.

How can I contact Novan?

Novan's mailing address is 4105 HOPSON ROAD, MORRISVILLE NC, 27560. The company can be reached via phone at 919-485-8080 or via email at [email protected]


MarketBeat Community Rating for Novan (NASDAQ NOVN)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  203 (Vote Outperform)
Underperform Votes:  263 (Vote Underperform)
Total Votes:  466
MarketBeat's community ratings are surveys of what our community members think about Novan and other stocks. Vote "Outperform" if you believe NOVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NOVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/29/2020 by MarketBeat.com Staff

Featured Article: Balance Sheet

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel